Prospects for the development of novel anti-hyperlipidemic drugs

Giuseppe Derosa, Sibilla Salvadeo, Arrigo F G Cicero

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Hyperlipidemia is a well-established risk factor for atherogenesis and cardiovascular disease. Statins have been the cornerstone of treatment for hyperlipidemia in recent years and have significantly contributed to the improvement of cardiovascular disease therapy. However, novel antihyperlipidemic agents that have been developed over the last decade possess the capacity to significantly reduce plasma lipoproteins. This review analyzes the pharmacological profile, effectiveness and safehj of some promising drugs that are either already in clinical use (eg, ezetimibe and nicotinic acid) or under study (eg, acyl-CoA cholesterol acyltransferase inhibitors, cholesteryl ester transfer protein inhibitors and apolipoprotein A-IMilano).

Original languageEnglish
Pages (from-to)826-833
Number of pages8
JournalCurrent Opinion in Investigational Drugs
Volume7
Issue number9
Publication statusPublished - Sep 2006

Fingerprint

Hyperlipidemias
Cardiovascular Diseases
Anticholesteremic Agents
Sterol O-Acyltransferase
Apolipoproteins A
Cholesterol Ester Transfer Proteins
Hypolipidemic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Niacin
Pharmaceutical Preparations
Lipoproteins
Atherosclerosis
Pharmacology
Therapeutics
Ezetimibe

Keywords

  • Acyl-CoA cholesterol acyltransferase inhibitors
  • Apolipoprotein A-I
  • Atherosclerosis
  • Cholesteryl ester transfer protein inhibitors
  • Dyslipidemia
  • Ezetimibe
  • Microsomal triglyceride transfer protein inhibitors
  • Nicotinic acid

ASJC Scopus subject areas

  • Pharmacology

Cite this

Prospects for the development of novel anti-hyperlipidemic drugs. / Derosa, Giuseppe; Salvadeo, Sibilla; Cicero, Arrigo F G.

In: Current Opinion in Investigational Drugs, Vol. 7, No. 9, 09.2006, p. 826-833.

Research output: Contribution to journalArticle

@article{0111ccc7df314fc4a3c14477ea9ca796,
title = "Prospects for the development of novel anti-hyperlipidemic drugs",
abstract = "Hyperlipidemia is a well-established risk factor for atherogenesis and cardiovascular disease. Statins have been the cornerstone of treatment for hyperlipidemia in recent years and have significantly contributed to the improvement of cardiovascular disease therapy. However, novel antihyperlipidemic agents that have been developed over the last decade possess the capacity to significantly reduce plasma lipoproteins. This review analyzes the pharmacological profile, effectiveness and safehj of some promising drugs that are either already in clinical use (eg, ezetimibe and nicotinic acid) or under study (eg, acyl-CoA cholesterol acyltransferase inhibitors, cholesteryl ester transfer protein inhibitors and apolipoprotein A-IMilano).",
keywords = "Acyl-CoA cholesterol acyltransferase inhibitors, Apolipoprotein A-I, Atherosclerosis, Cholesteryl ester transfer protein inhibitors, Dyslipidemia, Ezetimibe, Microsomal triglyceride transfer protein inhibitors, Nicotinic acid",
author = "Giuseppe Derosa and Sibilla Salvadeo and Cicero, {Arrigo F G}",
year = "2006",
month = "9",
language = "English",
volume = "7",
pages = "826--833",
journal = "Current Opinion in Investigational Drugs",
issn = "1472-4472",
publisher = "Current Drugs Ltd.",
number = "9",

}

TY - JOUR

T1 - Prospects for the development of novel anti-hyperlipidemic drugs

AU - Derosa, Giuseppe

AU - Salvadeo, Sibilla

AU - Cicero, Arrigo F G

PY - 2006/9

Y1 - 2006/9

N2 - Hyperlipidemia is a well-established risk factor for atherogenesis and cardiovascular disease. Statins have been the cornerstone of treatment for hyperlipidemia in recent years and have significantly contributed to the improvement of cardiovascular disease therapy. However, novel antihyperlipidemic agents that have been developed over the last decade possess the capacity to significantly reduce plasma lipoproteins. This review analyzes the pharmacological profile, effectiveness and safehj of some promising drugs that are either already in clinical use (eg, ezetimibe and nicotinic acid) or under study (eg, acyl-CoA cholesterol acyltransferase inhibitors, cholesteryl ester transfer protein inhibitors and apolipoprotein A-IMilano).

AB - Hyperlipidemia is a well-established risk factor for atherogenesis and cardiovascular disease. Statins have been the cornerstone of treatment for hyperlipidemia in recent years and have significantly contributed to the improvement of cardiovascular disease therapy. However, novel antihyperlipidemic agents that have been developed over the last decade possess the capacity to significantly reduce plasma lipoproteins. This review analyzes the pharmacological profile, effectiveness and safehj of some promising drugs that are either already in clinical use (eg, ezetimibe and nicotinic acid) or under study (eg, acyl-CoA cholesterol acyltransferase inhibitors, cholesteryl ester transfer protein inhibitors and apolipoprotein A-IMilano).

KW - Acyl-CoA cholesterol acyltransferase inhibitors

KW - Apolipoprotein A-I

KW - Atherosclerosis

KW - Cholesteryl ester transfer protein inhibitors

KW - Dyslipidemia

KW - Ezetimibe

KW - Microsomal triglyceride transfer protein inhibitors

KW - Nicotinic acid

UR - http://www.scopus.com/inward/record.url?scp=33748658041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748658041&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 826

EP - 833

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1472-4472

IS - 9

ER -